Zealand Pharma Secures USD 100 Million Royalty Sale with Royalty Pharma for Rusfertide Economics

With the FDA PDUFA date for rusfertide landing in Q3 2026 and Takeda holding global commercialization responsibility, Zealand Pharma has moved to convert a contingent royalty entitlement into immediate capital, a structural decision that separates financial exposure from regulatory accountability ahead of a potential NDA decision.

Under the agreement signed August 12, 2026, Zealand Pharma receives USD 100 million from Royalty Pharma in exchange for its economic interests in rusfertide (PTG-300), a first-in-class investigational subcutaneous hepcidin mimetic under review for adults with polycythemia vera. The payment is structured in two tranches: USD 50 million at closing and USD 50 million on the first anniversary. Zealand Pharma retains a residual 0.25% royalty on annual global net sales exceeding USD 1.5 billion; Royalty Pharma holds 0.75% above that same threshold.

The royalty interest originated from a 2012 research collaboration between Zealand Pharma and Protagonist Therapeutics focused on disulfide-rich peptides. That collaboration was terminated in 2014, with payment obligations clarified through a 2021 settlement. Protagonist subsequently licensed rusfertide to Takeda in January 2024 under a worldwide license and collaboration agreement, establishing Takeda as the commercial and regulatory lead for the asset.

For QA directors and regulatory affairs leads tracking the rusfertide NDA, the transaction does not alter the regulatory chain of responsibility. Takeda remains accountable for GMP compliance, supply chain readiness, and post-approval commitments under 21 CFR Part 211 and applicable ICH frameworks. Zealand Pharma's divestiture of the royalty stream is a financial restructuring, not a change in the drug's development or manufacturing governance.

Zealand Pharma's CFO Henriette Wennicke framed the deal as capital redeployment aligned with the company's Metabolic Frontier 2030 strategy, directing proceeds toward its obesity and metabolic health pipeline rather than a legacy hematology royalty. Royalty Pharma CEO Pablo Legorreta noted the transaction as a second collaboration with Zealand Pharma, consistent with Royalty Pharma's model of funding life science innovation through royalty acquisitions.

The FDA's PDUFA decision on rusfertide will serve as the first measurable checkpoint against which Royalty Pharma's USD 75 million net royalty position, and the residual interest Zealand Pharma retains above the USD 1.5 billion sales threshold, will be assessed.

Source: Zealand Pharma A/S via GlobeNewswire, August 12, 2026.